Oric Pharmaceuticals Inc (ORIC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has a cash flow conversion efficiency ratio of -0.083x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.61 Million) by net assets ($381.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Oric Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Oric Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Oric Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oric Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See ORIC operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dianguang Explosion-proof Technology Co Ltd
SHE:002730
|
-0.019x |
|
Liquidity Services Inc
NASDAQ:LQDT
|
0.132x |
|
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
|
-0.009x |
|
Zillow Group Inc
NASDAQ:ZG
|
0.045x |
|
Yihai International Holding Ltd
F:YIR
|
0.024x |
|
Alphamin Res
V:AFM
|
0.124x |
|
Cpi Fim SA
WAR:OPG
|
0.001x |
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Oric Pharmaceuticals Inc from 2017 to 2025. View Oric Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $384.36 Million | $-113.37 Million | -0.295x | +36.35% |
| 2024-12-31 | $243.12 Million | $-112.66 Million | -0.463x | -21.19% |
| 2023-12-31 | $224.09 Million | $-85.69 Million | -0.382x | -13.15% |
| 2022-12-31 | $222.35 Million | $-75.14 Million | -0.338x | -54.94% |
| 2021-12-31 | $272.98 Million | $-59.54 Million | -0.218x | -39.62% |
| 2020-12-31 | $289.78 Million | $-45.27 Million | -0.156x | +41.60% |
| 2019-12-31 | $87.97 Million | $-23.53 Million | -0.267x | -183.32% |
| 2018-12-31 | $-64.43 Million | $-20.68 Million | 0.321x | +139.65% |
| 2017-12-31 | $25.73 Million | $-20.83 Million | -0.810x | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more